Omeros(OMER) - 2022 Q4 - Earnings Call Transcript

The $408 million now in hand provides Omeros the flexibility simply to pay off any or all of the $95 million of convertible debt that matures this November, while continuing to fund operations and advancing our multiple development programs well into 2025. Detailed clinical data from that study were presented in December at the Annual Meeting of the American Society of Hematology. Based on clinical data to-date, we expect that we will be able to achieve once quarterly dosing with OMS906 either intravenously ...